Strategic Financial Concepts LLC Makes New Investment in The Chemours Company (NYSE:CC)

Strategic Financial Concepts LLC bought a new stake in shares of The Chemours Company (NYSE:CC) during the 4th quarter, Holdings Channel reports. The fund bought 21,135 shares of the specialty chemicals company’s stock, valued at approximately $357,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Inspire Investing LLC increased its holdings in shares of Chemours by 29.8% in the 3rd quarter. Inspire Investing LLC now owns 20,276 shares of the specialty chemicals company’s stock worth $412,000 after purchasing an additional 4,658 shares in the last quarter. Creative Planning raised its holdings in Chemours by 66.6% in the 3rd quarter. Creative Planning now owns 44,228 shares of the specialty chemicals company’s stock worth $899,000 after purchasing an additional 17,682 shares during the period. Twelve Points Wealth Management LLC grew its holdings in Chemours by 143.2% during the third quarter. Twelve Points Wealth Management LLC now owns 54,835 shares of the specialty chemicals company’s stock valued at $1,114,000 after purchasing an additional 32,287 shares during the period. Bfsg LLC boosted its position in shares of Chemours by 71.1% in the third quarter. Bfsg LLC now owns 6,860 shares of the specialty chemicals company’s stock worth $139,000 after purchasing an additional 2,851 shares during the period. Finally, nVerses Capital LLC bought a new position in Chemours in the 3rd quarter worth $207,000. 76.26% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on CC. Barclays upped their target price on shares of Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Mizuho lowered their price objective on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $25.00 price objective on shares of Chemours in a research note on Thursday, December 12th. The Goldman Sachs Group lowered their price objective on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley lowered their target price on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $24.11.

Chemours Stock Performance

NYSE:CC opened at $17.53 on Thursday. The stock has a market capitalization of $2.62 billion, a P/E ratio of 35.06 and a beta of 1.81. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The Chemours Company has a fifty-two week low of $15.10 and a fifty-two week high of $30.69. The company has a 50 day moving average price of $18.54 and a 200 day moving average price of $19.14.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.